Omeros (OMER) Net Cash Flow (2010 - 2026)
Omeros (OMER) posted Net Cash Flow of -$7.8 million for Q1 2026, down 206.73% sequentially from $7.3 million in Q4 2025, and down 1000.58% YoY from $861000.0 in Q1 2025.
Analysis
Omeros (OMER) Net Cash Flow (2010 - 2026) Analysis & Trends
Omeros has reported Net Cash Flow for 17 years, with the latest figure at -$7.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 1000.58% year-over-year to -$7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 196.91% YoY) and the FY2025 annual result came in at $6.3 million, up 268.96% from the prior year.
- Net Cash Flow retreated to -$7.8 million in Q1 2026 per OMER's latest filing, from $7.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $131.4 million in Q3 2022 and troughed at -$134.5 million in Q4 2022.
- A 5-year average of -$5.8 million and a median of $289000.0 in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 2585.28% in 2022, down 6135.23% in 2022.
- Over 5 years, Net Cash Flow stood at -$134.5 million in 2022, then surged by 82.5% to -$23.5 million in 2023, then soared by 107.98% to $1.9 million in 2024, then jumped by 286.64% to $7.3 million in 2025, then sank by 206.73% to -$7.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$7.8 million, $7.3 million, and $491000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 82,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82,000.00 |
| Mar 31, 2026 | -7.75 Mn |
| Dec 31, 2025 | 7.31 Mn |
| Sep 30, 2025 | 443,000.00 |
| Jun 30, 2025 | -2.36 Mn |
| Mar 31, 2025 | 861,000.00 |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | -599,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Mar 31, 2024 | -5.27 Mn |
| Dec 31, 2023 | -23.54 Mn |
| Sep 30, 2023 | 24.04 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | -7.18 Mn |
| Dec 31, 2022 | -134.52 Mn |
| Sep 30, 2022 | 131.40 Mn |
| Jun 30, 2022 | 5.17 Mn |
| Mar 31, 2022 | -91.85 Mn |
| Dec 31, 2021 | 93.39 Mn |
| Sep 30, 2021 | -5.29 Mn |